Fill the clinical gap of relapsed and refractory osteosarcoma in the past 30 years. Chinese original B7-H3 ADC shines with ESMO 2026

On October 26th, at the 2026 European Society of Oncology (ESMO) Annual Meeting held in Madrid, Spain, Professor Xie Lu from Peking University People's Hospital orally presented the results of the ARTEMIS-011III study in the form of the latest breakthrough abstract (LBA) at the Chair's Seminar. The results showed that Hansen Pharmaceutical's Rui Kang Li Fu Tuo Ta monoclonal antibody (B7-H3 ADC) significantly improved the median progression free survival, reduced the risk of disease progression or death by 67%, and controlled the disease in 76% of relapsed or refractory adolescent and adult osteosarcoma patients aged ≥ 12 years who failed at least second-line treatment.